RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

 
  • Regulatory NewsRegulatory News

    FDA to Begin Issuing Deficiency Review Letters to Generic Drugmakers

    The US Food and Drug Administration (FDA) on Friday published draft guidance that would establish a new type of letter the agency sends to generic drugmakers to provide applicants with preliminary thoughts on possible deficiencies of an abbreviated new drug application (ANDA). Thanks to the recently reauthorized Generic Drug User Fee Amendments (GDUFA II), FDA will issue Deficiency Review Letters (DRLs) and information requests (IRs) to obtain further information ...
  • Regulatory NewsRegulatory News

    Amgen Challenge of FDA Decision on Pediatric Exclusivity Could Have Wider Implications

    Back in May, the US Food and Drug Administration (FDA) denied a six-month extension of market exclusivity for Amgen's blockbuster Sensipar (cinacalcet), resulting in lawsuit filed by the drugmaker. A JAMA viewpoint published Wednesday argues that a decision in Amgen's favor could end up diminishing FDA's ability to encourage clinically meaningful pediatric studies. The case centers on the interpretation of how companies "fairly respond" to FDA's written requests ...
  • Regulatory NewsRegulatory News

    FDA Updates Guidance on Resolving Scientific, Medical Disputes

    The US Food and Drug Administration (FDA) has further clarified and updated its guidance on the system for resolving complicated medical and scientific disagreements between drug sponsors and the agency. The draft guidance is meant for cases when a sponsor may disagree with FDA and a dispute arises. The disputes often involve complex scientific and/or medical matters, so FDA deems it critical to have procedures in place to help ensure an open, prompt discussion. The rev...
  • Japan Joins Switzerland, Australia on List of Countries With API Quality Standards Equal to EU

    On 2 July 2013, new rules are set to go into effect in the European Union that radically change the process by which active pharmaceutical ingredients (APIs) manufactured outside the EU enter into the region. And while many countries are scrambling to get basic systems into place that will allow the manufacturers they regulate to meet the rules, Japan has now joined a small but elite group of nations that will be able to bypass many of the rules' most onerous provisions. ...
  • Legislation Introduced to Require 'Plain Writing' for all Regulations

    The US Food and Drug Administration (FDA) could be statutorily required to use "plain writing" in all of its future regulations if a piece of proposed legislation has its way. The proposed bill, The Plain Writing Act for Regulations of 2012 , would "require that Federal regulations use plain writing to enhance public understanding of regulations" in the hopes that such language would "increase the level of public participation in the rulemaking process." The bill, intr...
  • Analysis: FDA Warning Letters in 2011 Mostly Focused on Batch Failures

    An analysis of US Food and Drug Administration (FDA) warning letters issued in 2011 shows the majority of all facilities receiving a warning letter were deficient in areas relating to batch failure investigation , reports In-Pharma Technologist . "In the manufacturing-related warning letters analyzed by in-Pharma Technologist, FDA made 211 numbered observations," of which 10% were related to the company not investigating batch failures. Despite only 10% of all obs...